AstraZeneca
AstraZeneca is a high-quality pharma company with a strong portfolio of commercial products that lead to better overall health outcomes for patients, who are often suffering from life-threatening or debilitating illness. The company's products treat a broad range of issues and target areas of high unmet need, particularly in the oncology and rare disease portfolios.
Website besuchen- Unternehmenswert
- US$231.5 bn
- Region
- UK
- Thema
- Health
- Unterthema
- Pharmaceutical therapies
Impact-Bewertung
AstraZeneca has a diverse portfolio of therapies, often treating life threatening or rare diseases. In lung cancer the five year survival rate is only 24%, for example, however this has improved from a mere 5% in c. 2018. This is, in part, thanks to a number of AstraZeneca’s drugs that have received breakthrough designation from the FDA which means that they have shown evidence of substantial improvement in serious conditions.
Fundamentale Qualität
The disease areas AstraZeneca focuses on have strong structural growth drivers from ageing populations and lifestyle factors. The company has consistently demonstrated industry-leading returns on R&D investment and the strong pipeline is supportive of future growth. Healthcare access is central within its sustainability policy as seen via affordability programmes in over 20 low- and middle- income countries.
UN-Nachhaltigkeitsziele
AstraZeneca’s therapies support SDG 3 in the context of reducing mortality form non-communicable diseases through treatment.
Mehr erfahrenRisiko negativer Auswirkungen
- Side-effects from pharmaceuticals
- Product pricing restricts access for poor communities
- Plastic waste from packaging
- Animal testing of pharmaceuticals
Verwandte Einblicke Verwandte Inhalte
Sustainable
The next constraint on AI is not just energy, it's also water
Von Ty Lee
10. März 2026 | 3 min read
Sustainable
From villain to saviour – renewable energy is coming to the rescue
Von WHEB Investment Team
17. Feb. 2026 | 6 min read
Sustainable
Are EVs really rolling backwards?
Von WHEB Investment Team
19. Jan. 2026 | 5 min read
Sustainable
Sustainable investment trends for 2026
Von Seb Beloe
19. Jan. 2026 | 5 min read